Home›Elvitegravir›Elvitegravir + Velpatasvir And Sofosbuvir

Does Elvitegravir Interact with Velpatasvir And Sofosbuvir?

CDI records a unknown classification for Elvitegravir and Velpatasvir And Sofosbuvir. The stored summary is: 7.4 Drugs without Clinically Significant Interactions with EPCLUSA Based on drug interaction studies conducted with the components of EPCLUSA (sofosbuvir or velpatasvir) or EPCLUSA, no clinically significant drug interactions have been observed or are expected with the following drugs [see Clinical Pharmacology (12.3) ]: EPCLUSA: atazanavir/ritonavir, buprenorphine/naloxone, cyclosporine, darunavir/ritonavir, dolutegravir, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, methadone, naltrexone, raltegravir, or rilpivirine. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification: Unknown
Velpatasvir And Sofosbuvir Class: Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Management: Confirm exact products with your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Elvitegravir and your doctor is considering prescribing Velpatasvir And Sofosbuvir (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Elvitegravir(Stribild)+💊 Velpatasvir And Sofosbuvir(Sofosbuvir And Velpatasvir)

Severity & Interaction Details

ℹ️

unknown

Stored CDI classification: unknown

A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

Source

FDA drug label - velpatasvir and sofosbuvir

What this means in plain English

7.4 Drugs without Clinically Significant Interactions with EPCLUSA Based on drug interaction studies conducted with the components of EPCLUSA (sofosbuvir or velpatasvir) or EPCLUSA, no clinically significant drug interactions have been observed or are expected with the following drugs [see Clinical Pharmacology (12.3) ]: EPCLUSA: atazanavir/ritonavir, buprenorphine/naloxone, cyclosporine, darunavir/ritonavir, dolutegravir, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, methadone, naltrexone, raltegravir, or rilpivirine.

About Elvitegravir and Velpatasvir And Sofosbuvir

Velpatasvir And Sofosbuvir is a Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor. Elvitegravir is also sold under the brand name Stribild. Velpatasvir And Sofosbuvir additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - velpatasvir and sofosbuvir

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

PubMed

Metabolic Mechanisms of INSTI-Associated Weight Gain: A Multi-Omics Study in Male People with HIV.about Elvitegravir · 2026-07

PubMed

Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Treatment-Naive Patients Living With Human Immunodeficiency Virus (HIV) With High Viral Load: A Retrospective Observational Study.about Elvitegravir · 2026-07

PubMed

Preclinical Pharmacokinetics of a Triple-Combination Intravaginal Ring for HIV Prevention.about Elvitegravir · 2026-07

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Elvitegravir and Velpatasvir And Sofosbuvir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.